This inventor holds 4 USPTO granted patents and 2 published patent applications. Top assignees: Kyowa Kirin Co., Ltd., Kyoto University, Kyowa Kirin Co., Ltd.. Active years: 2024-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
3 out of 46 
2 out of 873 
1 out of 6 Years Active: 2024-2026
Title: The Innovative Mind of Masayuki KAI
Introduction
Masayuki KAI, based in Tokyo, Japan, is a notable inventor recognized for his contributions to the field of biotechnology. With one patented innovation, he has made significant strides in the medical industry, particularly in the area of therapeutic antibodies.
Latest Patents
KAI holds a patent for an Anti-human CCR1 monoclonal antibody. This monoclonal antibody binds to the human CC chemokine receptor 1 (CCR1), effectively inhibiting its activation. By targeting an extracellular region of the human CCR1, this invention obstructs the receptor's activation by the human CC chemokine ligand 15 (CCL15). KAI's innovation also includes various components such as antibody fragments, hybridomas producing the antibody, and methods for producing these antibodies or fragments, alongside their applications as therapeutic and diagnostic agents. The potential for treating and diagnosing CCR1-related diseases with his invention highlights its significance in the medical realm.
Career Highlights
Throughout his career, Masayuki KAI has engaged with reputable organizations, including Kyowa Kirin Co., Ltd. and Kyoto University. His time with these institutions has facilitated the advancement of his research and the development of his patented technology, allowing him to contribute to the scientific community through innovative discoveries.
Collaborations
Masayuki KAI has collaborated with esteemed colleagues such as Shinya Ogawa and Makoto Taketo. These partnerships have played a crucial role in his research endeavors and the successful development of his monoclonal antibody invention.
Conclusion
Masayuki KAI's contributions as an inventor and his dedication to advancing medical science through innovation demonstrate the vital role individual inventors play within the broader landscape of biotechnology. His patented Anti-human CCR1 monoclonal antibody stands as a testament to his skills and the potential impact of his work in the field of healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile